000110659 001__ 110659 000110659 005__ 20230519145522.0 000110659 0247_ $$2doi$$a10.37201/req/006.2021 000110659 0248_ $$2sideral$$a127452 000110659 037__ $$aART-2021-127452 000110659 041__ $$aspa 000110659 100__ $$aPinilla-Rello, A. 000110659 245__ $$aUtilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa 000110659 260__ $$c2021 000110659 5060_ $$aAccess copy available to the general public$$fUnrestricted 000110659 5203_ $$aIntroduction. Comparative “real life” data on the effectiveness and safety of ceftolozane/tazobactam (C/T) versus other regimens (aminoglycosides/colistin/combination), in the treatment of multi-resistant (MDR) and extremely resistant (XDR) Pseudomonas aeruginosa (PA), are needed to establish positions. Material and methods. Observational, retrospective study of patients with microbiological confirmation of MDR and XDR PA from July 2016 up to December 2018 in a tertiary hospital. Variables: age, sex, comorbidities, risk factors for multidrug resistance, variables related to infection, source of infection, microorganism and type of sample, antibiotic treatment, clinical cure, microbiological cure, recurrence, mortality on admission and 30 days post-discharge. Patients were classified according to received antibiotic treatment, C/T or aminoglycosides/colistin/combination Results. A total of 405 patients with PA MDR and XDR infection (73.1% men, mean age 63 ± 15 years) were studied. An 87.1% of PA XDR and a 12.9% MDR were observed. All patients received C/T as targeted therapy and in the amino-glycosides/colistin/combination group were 73.5%. Patients in the C/T group present worse prognostic factors: septic shock (30.0%) and catheterization (90.0%) (p<0.05). There were not statistically significant differences in microbiological cure (p=0.412), recurrence (p=0.880) and clinical cure (p=0.566). There were not statistically significant differences in mortality at admission (p=0.352) or at 30 days after discharge (p=0.231). A 17.2% of the patients with aminoglycosides/colistin/combination had acute kidney injury according to RIFLE criteria and 4.3% with C/T. Conclusions. The data obtained suggest that there have been no differences in effectiveness (clinical or microbiological cure) in favour of C/T, although, in the period studied, it was used in most cases in multitreated patients with a worse prognosis. Randomized and prospective studies would be needed to establish an adequate positioning. © The Author 2021. 000110659 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000110659 590__ $$a2.515$$b2021 000110659 592__ $$a0.44$$b2021 000110659 594__ $$a2.3$$b2021 000110659 591__ $$aPHARMACOLOGY & PHARMACY$$b206 / 279 = 0.738$$c2021$$dQ3$$eT3 000110659 593__ $$aMicrobiology (medical)$$c2021$$dQ3 000110659 591__ $$aMICROBIOLOGY$$b116 / 138 = 0.841$$c2021$$dQ4$$eT3 000110659 593__ $$aMedicine (miscellaneous)$$c2021$$dQ3 000110659 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000110659 700__ $$aHuarte-Lacunza, R. 000110659 700__ $$aMagallón-Martínez, A. 000110659 700__ $$aCazorla-Poderoso, L. 000110659 700__ $$aPereira-Blanco, O. 000110659 700__ $$aPérez-Moreno, M. 000110659 700__ $$aLarrodé-Leciñena, I. 000110659 700__ $$0(orcid)0000-0002-5808-7060$$aMartínez Álvarez, R. M. 000110659 700__ $$aLópez Calleja, A. I. 000110659 773__ $$g34, 5 (2021), 441-449$$pRev. esp. quimioter.$$tRevista española de quimioterapia$$x0214-3429 000110659 8564_ $$s209489$$uhttps://zaguan.unizar.es/record/110659/files/texto_completo.pdf$$yVersión publicada 000110659 8564_ $$s3287999$$uhttps://zaguan.unizar.es/record/110659/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000110659 909CO $$ooai:zaguan.unizar.es:110659$$particulos$$pdriver 000110659 951__ $$a2023-05-18-15:23:33 000110659 980__ $$aARTICLE